

Haematologica  
HAEMATOL/2017/187047  
Version 3

Safety and efficacy of plerixafor dose escalation for the mobilization of CD34+ hematopoietic progenitor cells in patients with sickle cell disease: interim results

Farid Boulad, Tsiporah Shore, Koen van Besien, Caterina Minniti, Mihaela Barbu-Stevanovic, Sylvie Wiener Fedus, Fabiana Perna, June Greenberg, Danielle Guarneri, Vijay Nandi, Audrey Mauguen, Karina Yazdanbakhsh, Michel Sadelain, and Patricia A. Shi

Disclosures: Sanofi-Genzyme provided the plerixafor for this study. Doris Duke Charitable Foundation provided funding for this study (to MS and PAS)

Contributions: PAS and MS conceived and designed the study and are co-PIs on the DDCF grant for this study. FB, TS, and KVB also designed the study. FB is the clinical trial PI; TS, KVB, PAS, and MS are co-investigators. MBS, FP, SWF, PAS, and MS designed, performed, and/or analyzed experiments. PAS and CM recruited study patients. JG, DG, TS, and KVB enrolled patients and supervised study procedures. KY, VN, and AM helped analyze study data. PAS, FB, and MS co-wrote the manuscript, with edits by KY, KVB, and TS.